Get the Stockscreener App
4.37
8.58%
-0.41
Entrada Therapeutics Inc stock is traded at $4.37, with a volume of 371.79K.
It is down -8.58% in the last 24 hours and down -36.57% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$4.78
Open:
$4.79
24h Volume:
371.79K
Relative Volume:
1.00
Market Cap:
$170.15M
Revenue:
$5.74M
Net Income/Loss:
$-166.12M
P/E Ratio:
-1.0931
EPS:
-3.9978
Net Cash Flow:
$-131.64M
1W Performance:
-22.93%
1M Performance:
-36.57%
6M Performance:
-67.77%
1Y Performance:
-29.29%
1-Day Range:
$4.345
$4.85
1-Week Range:
$4.1092
$5.69
52-Week Range:
$4.1092
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
4.37 | 170.15M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-01-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-11-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Oppenheimer | Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
View All
Entrada Therapeutics Inc Stock (TRDA) Latest News
TRDA 8-K & SEC Filings - Yahoo! Finance Canada
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 - GlobeNewswire Inc.
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study - GlobeNewswire Inc.
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity - Seeking Alpha
Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance Singapore
TRDA S-8 & SEC Filings - Yahoo! Finance Canada
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
MPM BioVentures 2014, L.P. Offloads 259,837 Shares of Entrada Therapeutics (NASDAQ: TRDA) at $7.11-$7.41 Each - Kalkine Media
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Australia
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program - The Manila Times
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Australia
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock - Investing.com
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares - Investing.com
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com India
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com UK
MPM funds sell Entrada (TRDA) shares, still hold stakes over 1.7M each - Stock Titan
MPM funds sell 259,837 Entrada Therapeutics (TRDA) shares over 3 days - Stock Titan
Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead By Investing.com - Investing.com South Africa
Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead By Investing.com - Investing.com India
Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com South Africa
MPM BIOVENTURES 2018, L.P. Disposes 86,482 Shares of Entrada Therapeutics Between September 1-3, 2026 - Kalkine Media
Entrada Therapeutics' R&D President Sethuraman Natarajan Forfeits 2,079 Shares at $7.14 Each on September 2, 2026 - Kalkine Media
Entrada Therapeutics CFO Wentworth Kory James Forfeits 1,733 Shares at $7.14 Each (NASDAQ: TRDA) - Kalkine Media
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com South Africa
TRDAEntrada Therapeutics Inc Revenue Breakdown - Finviz
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Canada
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com India
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Australia
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics - Investing.com
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com UK
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com UK
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan
MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan
Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) CFO stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) insider stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) COO holdings - Stock Titan
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares - Investing.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Liquidity Mapping Around (TRDA) Price Events - news.stocktradersdaily.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 09 '26 |
Sale |
7.13 |
28,837 |
205,608 |
3,885,115 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 09 '26 |
Sale |
7.13 |
28,837 |
205,608 |
3,885,115 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 08 '26 |
Sale |
7.41 |
192,500 |
1,426,425 |
3,913,952 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 04 '26 |
Sale |
7.11 |
38,500 |
273,735 |
4,106,452 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 04 '26 |
Sale |
7.11 |
38,500 |
273,735 |
4,106,452 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 03 '26 |
Sale |
7.17 |
32,263 |
231,326 |
4,144,952 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 03 '26 |
Sale |
7.17 |
32,263 |
231,326 |
4,144,952 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 02 '26 |
Sale |
7.19 |
25,131 |
180,692 |
4,177,215 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 02 '26 |
Sale |
7.19 |
25,131 |
180,692 |
4,177,215 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 01 '26 |
Sale |
7.06 |
29,088 |
205,361 |
4,202,346 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):